The Effect of Rosuvastatin on Aortic Stiffness in Hemodialysis Patients in the AURORA Study

Phase 3

Completed

• Conditions: Hypercholesterolemia

• Registration Number: NCT00240279
• Lead Sponsor: AstraZeneca

Brief Summary

To investigate the effect of rosuvastatin compared to placebo on the aortic stiffness in hemodialysis patients as measured by pulse wave velocity (at 3, 6 and 12 months)

Detailed Description

Not available

Study Timeline

• Study Start: 2003-01
• Study First Submitted: 2005-10-16
• Study First Submitted QC: 2005-10-16
• Study First Posted: 2005-10-18
• Primary Completion: 2008-10
• Study Completion: 2008-10
• Status Verified: 2010-11
• Last Update Submitted: 2010-11-18
• Last Update Posted: 2010-11-19

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

• Signed informed consent, between 50 and 80 years of age, end stage renal failure patients receiving hemodialysis

Exclusion Criteria

• Received statins within past 6 months, a clear indication for use of lipid altering drug, contra indication for lipid altering drug, history of statin induced myopathy items in very

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
To investigate the effect of rosuvastatin compared to placebo on the aortic stiffness in hemodialysis patients as measured by pulse wave velocity (at 3, 6 and 12 months)

Secondary Outcome Measures

Name	Time	Method
To investigate the effect of rosuvastatin compared to placebo on the aortic pressure wave in hemodialysis patients (at 3 months/ 6 months and 12 months).

Trial Locations

Locations (1)

Research Site; 🇳🇱 Nieuwegein, Netherlands